Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping
NCT05749588Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, TROP2 ADC, TQB2102, TQB2868 in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Mar 2023; status: recruiting.
02
Drugs
trastuzumab rezetecanTROP2 ADCTQB2102TQB2868
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05749588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749588.